Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech ( (EVAX) ) just unveiled an announcement.
On May 4, 2026, Evaxion A/S, a Nasdaq-listed clinical-stage TechBio firm, filed a Form 6-K in the United States to incorporate a new press release into its existing shelf and registration statements. The filing underscores the company’s ongoing capital markets activity as it advances AI-driven vaccine programs for cancer and infectious diseases.
On the same day, Evaxion announced plans to deliver a business update and report first-quarter 2026 financial results on May 7, 2026, before the opening of Nasdaq CM. Management will host a conference call and webcast, signaling continued engagement with investors and offering stakeholders fresh insight into operational progress, financial position and the maturation of its AI-Immunology vaccine pipeline.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based clinical-stage TechBio company that develops novel cancer and infectious disease vaccines using its proprietary AI-Immunology platform. The platform applies artificial intelligence to decode the human immune system, enabling rapid target discovery, drug design and development across a pipeline of personalized and off-the-shelf vaccine candidates addressing high unmet medical needs.
The company employs more than 40 specialists covering the value chain from discovery to clinical development, and focuses on transforming patient outcomes with innovative, targeted immunotherapies. Its AI-driven approach is clinically validated and designed to be scalable, positioning Evaxion as a niche player at the intersection of biotechnology, oncology and advanced computational science.
Average Trading Volume: 32,273
Technical Sentiment Signal: Sell
Current Market Cap: $37.49M
See more data about EVAX stock on TipRanks’ Stock Analysis page.